Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-641-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$96.30 million
Profitability
Miscellaneous
Employees327
OptionableOptionable
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) announced its earnings results on Monday, November, 5th. The medical equipment provider reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02. The medical equipment provider earned $24.70 million during the quarter, compared to the consensus estimate of $24.09 million. Intersect ENT had a negative net margin of 20.00% and a negative return on equity of 17.62%. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.15) EPS. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What guidance has Intersect ENT issued on next quarter's earnings?
Intersect ENT issued an update on its first quarter 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $28.36 million.Intersect ENT also updated its FY 2018 guidance to EPS.
What price target have analysts set for XENT?
7 brokerages have issued 12 month target prices for Intersect ENT's shares. Their predictions range from $28.00 to $48.00. On average, they anticipate Intersect ENT's share price to reach $38.6667 in the next twelve months. This suggests a possible upside of 34.4% from the stock's current price. View Analyst Price Targets for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (1/6/2019)
- 2. Northland Securities analysts commented, "We had specifically referenced this drug and these Phase-III studies as risks on the horizon for SINUVA in our note dated 10/03/18. The Phase – III data raise many questions in our mind about SINUVA outlook and the competitive landscape. Caution is warranted vis-a-vis SINUVA. Key Points The f/u for the 2-trials was 24-wks, Dupilumab + mometasone furoate (Nasonex) spray 51% reduction in nasal congestion / obstruction severity vs. 15% for the control arm of mometasone furoate spray in SINUS-24 trial. The numbers stood at 57% and 19% for SINUS-52 trial." (10/17/2018)
- 3. BTIG Research analysts commented, "Following this morning’s early earnings announcement, management discussed the issues underlying the weak report and reduced sales guidance. Most troubling to us was that instead of SINUVA being easily available via the specialty pharmacy channel, many payors are requiring doctors to either use a payor-affiliated specialty pharmacy partner or to use a buy-and-bill approach. This means doctors must pay to acquire SINUVA, then bill for it and hope they are paid back. While XENT mgmt believes this hurdle can be overcome by showing reluctant docs proof of payment and expanding the salesforce, we think it will be more difficult to change the way ENTs operate. We cut our SINUVA sales estimate for 2H and beyond while also dampening modeled growth rates for PROPEL." (8/2/2018)
- 4. Canaccord Genuity analysts commented, "We remain buyers ahead of trial data coming up in 4Q18 We believe the stock’s pullback presents opportunity ahead of a catalyst-rich period that is coming up in the near to medium-term. Specifically, we await results on long- term safety of rimegepant (acute treatment of migraine) and a Phase 3 trial on the orally-dissolving tablet (ODT) formulation of rimegepant. Given the behavior of the molecule in two Phase 3 trials so far (see here) and a validated mechanism (Allergan also reported positive results for its ubrogepant; see here), we expect these results to support a potential filing of rimegepant in 2019. a more detailed list of BHVN-related catalysts. We also continue to believe that rimegepant could be a meaningful player in the market for the acute treatment of migraine, and we are reiterating our BUY on BHVN." (8/1/2018)
Has Intersect ENT been receiving favorable news coverage?
News stories about XENT stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intersect ENT earned a news sentiment score of 3.7 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Are investors shorting Intersect ENT?
Intersect ENT saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,455,562 shares, an increase of 53.6% from the December 14th total of 947,515 shares. Based on an average daily volume of 361,760 shares, the short-interest ratio is presently 4.0 days. Currently, 4.9% of the shares of the stock are short sold. View Intersect ENT's Current Options Chain.
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Cantel Medical (CMD), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), K2M Group (KTWO), AtriCure (ATRC), Luminex (LMNX), Tactile Systems Technology (TCMD), Cryolife (CRY) and Orthofix Medical (OFIX).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 48)
- Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 60)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
- Mr. Richard E. Kaufman, Technical Advisor (Age 56)
- Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 54)
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boston Advisors LLC (0.14%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which institutional investors are buying Intersect ENT stock?
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $28.78.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $855.24 million and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
What is Intersect ENT's official website?
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
